VAULTREE
29.3.2023 15:01:28 CEST | Business Wire | Press release
Vaultree, the Data-In-Use Encryption leader, today announced that it has successfully achieved Google Cloud Ready - AlloyDB designation for AlloyDB for PostgreSQL, Google Cloud’s newest fully managed PostgreSQL-compatible database service for most demanding enterprise database workloads.
This market-expanding milestone follows Vaultree’s successful $12.8 million series A funding round, selection as the only Irish recipient of the European Innovation Council (EIC) grant and the appointment of renowned tech industry veteran Rinki Sethi to its executive board of directors.
Google Cloud Ready - AlloyDB is a new designation for the solutions of Google Cloud’s technology partners that integrate with AlloyDB. These partners have closely collaborated with Google Cloud to add support for AlloyDB into their solutions and tune their existing functionality for optimal outcomes. This designation recognizes the partner solutions that have met a core set of functional requirements and been validated in collaboration with Google Cloud engineering teams.
“Achieving the Google Cloud Ready - AlloyDB designation demonstrates that Vaultree’s data encryption in use capabilities have been validated by Google Cloud to integrate with AlloyDB to provide an excellent experience for customers,” said Ritika Suri, Director, Technology Partnerships at Google Cloud.
By earning this designation, Vaultree has proven its product has met a core set of functional and interoperability requirements when integrating with AlloyDB and refined documentation for ease of onboarding by the companies’ mutual customers. This designation enables customers to discover and have confidence that the Vaultree products they use today work well with AlloyDB and save time evaluating them.
As part of the program, Vaultree enjoys more opportunities to collaborate closely with Google Cloud partner engineering and AlloyDB teams to develop joint roadmaps.
Google Cloud’s ecosystem is designed to support industry-focused digital transformation. With this partnership, Vaultree enables customers to rely on end-to-end solutions through a reliable, fast and seamless integration of the most advanced encryption product on the market to rid themselves of the danger of plaintext data exposure.
“Breaches or leaks will continue to happen, no matter how many tools are in the first line of defense, but the second line of defense – encryption – has been neglected for decades because data still has to be decrypted in order to be worked with,” said Tilo Weigandt, COO and co-founder of Vaultree. “Our goal is to end that with our product and help enterprises to not just be compliant but secure and leave the worries behind.”
Vaultree with Google Cloud’s AlloyDB for PostgreSQL fulfills this goal, allowing customers to choose what to encrypt, and manage their own keys with zero learning and changes to the existing query languages, data structure, architecture, network topology or policies/permissions — all with minimal performance loss in the cloud.
“We are paving the way to a new era of cloud-based data protection by designing and offering the world’s first always-encrypted, Data-In-Use solution with unparalleled performance and simplicity, powered by Vaultree with Google’s AlloyDB for PostgreSQL,” said Ryan Lasmaili, CEO and co-founder of Vaultree. “Partnering with Google Cloud brings us reliability, flexibility and freedom to innovate and engage with a key player in an ever-changing industry to create the best data privacy solutions for enterprises of any kind, driving security and profitability, and accelerating digital transformation.”
To learn more about Vaultree’s expertise with AlloyDB, visit. To learn more about Google Cloud Ready - AlloyDB and its benefits, visit.
About Vaultree
Vaultree has developed the world’s first Fully Functional Data-in-Use Encryption solution that solves the industry’s fundamental security issue: persistent data encryption, even in the event of a leak. Vaultree enables enterprises, including those in the financial services and healthcare/pharmaceutical sectors, to mitigate the great financial, cyber, legal, reputational and business risk of a data breach in plain text. With Vaultree, organizations process, search and compute ubiquitous data at scale, without ever having to surrender encryption keys or decrypt server-side. If a leak occurs, Vaultree’s Data-In-Use encryption persists, rendering the data unusable to bad actors. Integrating Vaultree into existing database technologies is seamless, requiring no technology or platform changes. Vaultree is a privately held company based in Ireland and the U.S. For more information, please visit www.vaultree.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005299/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom